crinetics.png
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 12, 2024 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2024, the Compensation Committee of Crinetics’ Board of Directors...
crinetics.png
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 16:05 ET | Crinetics Pharmaceuticals, Inc.
Paltusotine NDA Submission in Acromegaly On Track for 2024 Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent...
crinetics.png
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
August 08, 2024 08:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the launch of the ACRO/TRUTH healthcare provider (HCP) educational website and initiative,...
crinetics.png
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
July 18, 2024 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024...
crinetics.png
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2024 19:29 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted...
crinetics.png
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
June 18, 2024 16:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur Of...
crinetics.png
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2024 18:35 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted...
crinetics.png
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
June 03, 2024 12:00 ET | Crinetics Pharmaceuticals, Inc.
100% of Participants (n=6) With CAH Maintained Androstenedione (A4) Below the Upper Limit of Normal at all Time Points on Atumelnant (80 mg) CAH Participants Achieved More Than a 90% Reduction of...
crinetics.png
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
June 03, 2024 12:00 ET | Crinetics Pharmaceuticals, Inc.
First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine ...
crinetics.png
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
May 30, 2024 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs....